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The incidence of pleural and pericardial effusion
is not higher in patients receiving dasatinib at
low doses. (Reply)
In a recent issue of this Journal, Krauth et al.1 reported
the development of extensive pleural or pericardial effu-
sions in 4 chronic myeloid leukemia (CML) patients treat-
ed for at least three months with average or low dose
(100 or 50 milligrams/day) dasatinib. The Authors con-
secutively treated 13 patients with dasatinib at 50 or 100
mg daily for at least three months (range 3-38), and
observed extensive pleural or pericardial effusion in
approximately 30% of the patients. They conclude that
CML patients treated with dasatinib are at risk of devel-
oping pleural or pericardial effusion, even when the drug
is administered at average (100 mg/day) or low (50
mg/day) doses, and independently from pre-existing pul-
monary or cardiac disease.
In our opinion, this information is misleading for sever-
al reasons. First, 2 of 4 patients developing a grade III/IV
pleural effusion were in accelerated phase. Several stud-
ies demonstrated that advanced disease CML, either in
accelerated or blastic phase, is significantly associated
with a higher risk of pleural effusion, independently of
dasatinib dose, together with history of cardiac disease,
hypertension and b.i.d schedule.2,3 Second, one out of 4
patients received an allogeneic stem cell transplantation
and suffered chronic graft-versus-host disease of the skin.
The Hammersmith group3 has reported that a previous
history of autoimmune disorders or a history of skin rash
during imatinib therapy are variables associated with
higher risk of developing a pleural or pericardial effusion.
Even if Krauth and co-workers did not describe the devel-
opment of skin rash during imatinib, it is possible to
hypothesize a history of autoimmune disease due to
chronic graft-versus-host disease of the skin. As a matter
of fact, 3 out of 4 patients reported in this paper had one
or more risk factors for developing pleural or pericardial
effusion already present at the time of starting dasatinib.
This information should be kept carefully in mind when
we read this paper, because the population of patients
treated was at high risk of developing fluid retention.  
Third, the conclusions expressed by Krauth et al.1 are in
contrast with results published on larger series of CML
patients treated with up to 100 mg/day. Porkka et al.4 pre-
sented the data on the incidence of pleural effusion in the
phase III trial for chronic phase patients comparing four
different dosages of dasatinib (Study 034). The occur-
rence of effusion of all grades was 14% in the 100 mg q.d
arm compared to 25% in the 70 mg b.i.d arm (P=0.021),
with a slight increase in the overall rate between the first
and second year of follow up. We recently published the
results from a real life-based Italian multicenter study on
114 CML patients in chronic phase treated with dasatinib
due to resistance or intolerance to imatinib.5 Patients’
characteristics are summarized in Table 1. Patients
received dasatinib at different doses, starting from at least
100 milligrams/day. As a matter of fact, patients experi-
encing a grade III-IV toxicity discontinued dasatinib or, if
possible, reduced the dose from 140 or 100
milligrams/day to 70 or 50 milligrams/day. When patients
maintained or improved their response even with low
doses of dasatinib, we decided to proceed with the toler-
ated dose of the drug. At the time of the analysis, 56
patients were receiving 50 or 70 milligrams/day of dasa-
tinib, whereas 58 patients were receiving 100 or 140 mil-
ligrams/day. Patients were treated with dasatinib for a
median time of 19 months (range 6-39).
Only 4 of 114 patients (3%) and one of 114 (0.8%) suf-
fered from a grade III-IV pleural or pericardial effusion.
Remarkably, none of the 56 subjects receiving low doses
of dasatinib (50 or 70 mg/day) experienced a grade III-IV
pleural effusion.  
Pleural, as well as pericardial effusions are potentially
serious and must be treated promptly.6 However, pleural
effusions are usually manageable, generally mild to mod-
erate in severity, and occur more frequently in advanced
phase of disease, in elderly patients with concomitant
comorbidities and in patients treated with high doses. In
conclusion, we agree that the possible occurrence of fluid
retention should not be underestimated while treating
CML patients with dasatinib, in particular if they present
comorbidities. On the other hand, our data,5 drawn from
a real-life approach, are reassuring not only regarding effi-
cacy, but even regarding tolerability and feasibility of
dasatinib treatment at low doses. A word of caution
should be expressed on the possible overestimation of
the incidence of effusion, a fact that could prevent physi-
cians administering a drug such as dasatinib, which is
effective and generally safe for CML patients, especially
at average or low doses.
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Pts aged >60 years 50 (40%)







Intolerant to imatinib 16
Resistant and intolerant 10
Time in dasatinib, months
Median 19
Range 6-43
Pleural effusion (all 114 patients) 4 (3%)
Pericardial effusion (all 114 patients) 1 (0.8%)
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